Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Writeresult Turns to Digital Pen and Paper Technology for Clinical Trials

June 16, 2011 12:29 pm | News | Comments

Anoto Group, a provider of digital pen and paper technology and ExpeData, a digital writing software company announced that writeresult, a data management solutions provider for clinical research, has committed to use their technologies for a global clinical trial.


Drug May Improve Glycemic Control in Diabetics

June 16, 2011 12:15 pm | News | Comments

Results of an observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetes on insulin achieve optimal control of their blood glucose levels.


CytRx Reports Bafetinib Results

June 16, 2011 12:09 pm | News | Comments

CytRx announced results from its ENABLE Phase 2 trial that demonstrated bafetinib, the company’s Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.


IntraLinks Survey Shows Need for Reporting Tools

June 16, 2011 11:58 am | News | Comments

IntraLinks announced the results of the IntraLinks Global Investigator Site survey that looked at the effectiveness of methods currently used for clinical trial document.



June 16, 2011 7:33 am | Product Releases | Comments

The Cole-Parmer IKA BR 10 Bioreactor features an interface that controls all of the photosynthetic variables of lighting, motion, pH value, and temperature. The unit takes up less than half the space of a traditional bioreactor.


Mass Spectrometry Platform

June 16, 2011 7:24 am | Product Releases | Comments

PerkinElmer Inc. launched its AxION Mass Spectrometry platform. The AxION hardware and software platform delivers rapid and accurate mass identification and quantification to ensure safer pharmaceutical products.


Brazil Certifies Celerion Operations

June 16, 2011 7:15 am | News | Comments

Celerion announced that its clinical research operations in Belfast and its clinical research and bioanalytical services operations in Lincoln, Nebraska, have been certified by the Brazilian National Health Surveillance Agency (ANVISA).


Altered RNA May Lead to Treatment for Genetic Ailments

June 16, 2011 7:09 am | News | Comments

Scientists have discovered an entirely new way to change the genetic code. The findings may ultimately help researchers alter the course of devastating genetic disorders, such as cystic fibrosis, muscular dystrophy, and many forms of cancer.


ARIAD to File AP26113 IND

June 16, 2011 7:03 am | News | Comments

ARIAD Pharmaceuticals, Inc. announced the results of preclinical studies on AP26113, showing that AP26113 has a novel profile as a dual inhibitor of ALK and EGFR, an additional validated target in non-small cell lung cancer.


BMS Immunosuppressant Granted FDA Approval

June 16, 2011 6:54 am | News | Comments

Nulojix, the first new type of drug in more than a decade for keeping transplanted kidneys functioning, has won approval from the Food and Drug Administration.


Scientists Find Cause of Parkinson's Treatment Side Effects

June 16, 2011 6:50 am | News | Comments

Researchers in Canada have discovered why dopamine replacement therapy, which is used to manage motor symptoms associated with Parkinson's disease, can, at times, adversely affect cognition.


Report: 'Mist' Spiriva More Dangerous Than Placebo

June 16, 2011 6:35 am | News | Comments

An analysis in the British Medical Journal said patients who took a version of lung drug Spiriva in clinical trials were 52 percent more likely to die than patients who took a placebo.


Adaptimmune Metastatic Melanoma Phase 1 and Phase 2 Clinical Trial

June 15, 2011 12:20 pm | News | Comments

Adaptimmune announced it has opened a Phase 1 and Phase 2 cohort, open label clinical trial in metastatic melanoma at Washington University.


Survival Cell Signaling Pathway

June 15, 2011 12:13 pm | News | Comments

In a study at UCLA's Jonsson Comprehensive Cancer Center, researchers found when a common type of prostate cancer was treated with conventional hormone ablation therapy blocking androgen production or androgen receptor (AR) function, the cancer adapted by activating a survival cell signaling pathway.


Low-Carbohydrate, High-Protein Diets May Lower Cancer Risk

June 15, 2011 12:09 pm | News | Comments

Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study conducted at the British Columbia Cancer Research Center.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.